Search results

Page results

• A massive thank you to our amazing staff

  Today is the 72 anniversary of the NHS – and it is dedicated to our amazing staff.

• UCLH researchers first in the world to trial novel cancer treatment

  Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.

• Coping with Nasal Surgery: What to Expect and How to Support Yourself

  Psychological guidance to help you prepare, cope, and recover.

• Major clinical trial aims to combat post-surgical health inequalities

  A team of clinicians and researchers at UCLH and UCL have been awarded a £2.8 million grant to combat health inequalities in patients having major surgery.

• Cystic fibrosis drug tested to fight inflammation in COVID-19

  Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.

• UCLH to trial second COVID-19 vaccine

  UCLH is to trial a COVID-19 vaccine developed by Imperial College London.

• Government programme to reduce theatre waste launched at UCLH

  Sustainability in healthcare was top of the agenda on Tuesday when the Department of Health and Social Care selected UCLH as the site to launch a new programme to reduce the reliance on single-use items in the UK health system.

• Millions of men could benefit from faster scan to diagnose prostate cancer

  A quicker, cheaper MRI scan is just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, according to clinical trial results led by UCLH, UCL and the University of Birmingham.

• How to remove proxy access from your MyCare account

  If you need to remove or revoke proxy access from your MyCare account.

• Antibody levels vary according to vaccine type and previous infection with COVID-19

  Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.